Initial outcomes of a dedicated multidisciplinary non-alcoholic fatty liver disease clinic: a retrospective cohort study

被引:2
作者
Commins, Isabella [1 ]
Clayton-Chubb, Daniel [1 ,2 ]
Melton, Sarah [3 ]
Majeed, Ammar [1 ,2 ]
Kemp, William [1 ,2 ]
Roberts, Stuart K. [1 ,2 ,4 ]
机构
[1] Alfred Hlth, Dept Gastroenterol, Melbourne, Australia
[2] Monash Univ, Cent Clin Sch, Dept Med, Melbourne, Australia
[3] Alfred Hlth, Dept Nutr & Dietet, Melbourne, Australia
[4] Alfred Ctr, Dept Gastroenterol, 99 Commercial Rd, Melbourne 3004, Australia
关键词
NAFLD; MAFLD; multidisciplinary; liver function tests; FibroScan; WEIGHT-LOSS; MANAGEMENT; DIAGNOSIS; IMPROVEMENT; RISK;
D O I
10.1111/imj.16055
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundNon-alcoholic fatty liver disease (NAFLD) is a major healthcare burden. Real-world outcomes in dedicated tertiary care settings in Australia remain unknown. AimTo evaluate the initial outcomes of patients referred to a dedicated multidisciplinary tertiary care NAFLD clinic. MethodsRetrospective review of all adult patients with NAFLD who attended a dedicated tertiary care NAFLD clinic between January 2018 and February 2020 and who had two clinic visits and FibroScans at least 12 months apart. Demographic and health-related clinical and laboratory data were extracted from electronic medical records. Key outcome measures were serum liver chemistries, liver stiffness measurement (LSM) and weight control at 12 months. ResultsA total of 137 patients with NAFLD were included. Median (interquartile range (IQR)) follow-up time was 392 days (343-497 days). One hundred and eleven patients (81%) achieved weight control (i.e. weight loss or stability). Markers of liver disease activity were significantly improved, including median (IQR) serum alanine aminotransferase (48 (33-76) vs 41 (26-60) U/L, P = 0.009) and aspartate aminotransferase (35 (26-54) vs 32 (25-53) U/L, P = 0.020). Median (IQR) LSM across the whole cohort was significantly improved (8.4 (5.3-11.8) vs 7.0 (4.9-10.1) kPa, P = 0.001). No significant reduction was observed in mean body weight or the frequency of metabolic risk factors. ConclusionsThis study highlights a new model of care for patients with NAFLD and demonstrates promising initial outcomes in relation to significant reductions in markers of liver disease severity. Although most patients achieved weight control, further refinements are needed to achieve significant weight reduction including more frequent and structured dietetic and/or pharmacotherapeutic interventions.
引用
收藏
页码:2065 / 2072
页数:8
相关论文
共 22 条
  • [1] Nonalcoholic fatty liver disease burden: Australia, 2019-2030
    Adams, Leon A.
    Roberts, Stuart K.
    Strasser, Simone, I
    Mahady, Suzanne E.
    Powell, Elizabeth
    Estes, Chris
    Razavi, Homie
    George, Jacob
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (09) : 1628 - 1635
  • [2] Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes
    Ahmed, Aijaz
    Wong, Robert J.
    Harrison, Stephen A.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (12) : 2062 - 2070
  • [3] Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management
    Armstrong, Matthew J.
    Hazlehurst, Jonathan M.
    Parker, Richard
    Koushiappi, Elena
    Mann, Jake
    Khan, Sheeba
    Philips, Angela
    Chandler, Liz
    Johnson, Jill
    Round, Maria
    Haydon, Geoffrey
    Karamat, Mohammad A.
    Newsome, Philip N.
    Tomlinson, Jeremy W.
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2014, 107 (01) : 33 - 41
  • [4] Australian Institute of Health and Welfare, 2018, OV OB
  • [5] Chalasani NP, 2017, HEPATOLOGY, V66, p303A
  • [6] Association of clinically significant weight loss with number of patient visits and months of attendance at an Australian multidisciplinary weight management clinic
    Chen, Juliana
    Kaur, Harpreet
    Jaques, Joanna
    Rock, Zoe
    Dean, Catherine M.
    Lord, Reginald, V
    Preda, Veronica
    [J]. CLINICAL OBESITY, 2022, 12 (03)
  • [7] Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease
    Clark, JM
    Alkhuraishi, ARA
    Solga, SF
    Alli, P
    Diehl, AM
    Magnuson, TH
    [J]. OBESITY RESEARCH, 2005, 13 (07): : 1180 - 1186
  • [8] Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience
    Cobbold, Jeremy F. L.
    Raveendran, Sarrah
    Peake, Christopher M.
    Anstee, Quentin M.
    Yee, Michael S.
    Thursz, Mark R.
    [J]. FRONTLINE GASTROENTEROLOGY, 2013, 4 (04) : 263 - 269
  • [9] Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss
    Dixon, JB
    Bhathal, PS
    Hughes, NR
    O'Brien, PE
    [J]. HEPATOLOGY, 2004, 39 (06) : 1647 - 1654
  • [10] Weight loss and non-alcoholic fatty liver disease: Falls in gamma-glutamyl transferase concentrations are associated with histologic improvement
    Dixon, John B.
    Bhathal, Prithi S.
    O'Brien, Paul E.
    [J]. OBESITY SURGERY, 2006, 16 (10) : 1278 - 1286